CH
SABSW icon

CVI Holdings’s SAB Biotherapeutics Warrant SABSW Stock Holding History

CVI Holdings’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-58,320
Closed -$104K – 954
2021
Q4 		$104K Sell
58,320
-116,680
-67% -$214K 0.01% 635
2021
Q3 		$158K Hold
175,000
– – 0.01% 553
2021
Q2 		$161K Buy
+175,000
New +$127K 0.01% 509

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CVI Holdings's SABSW Position: Q1 2022 in Review

CVI Holdings sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2022, closing a stake of 58,320 shares — an estimated $104K sold.

CVI Holdings first reported a position in SABSW in Q2 2021 and held it in 3 quarters. The position peaked at $161K in Q2 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q1 2022.

  • CVI Holdings reported no remaining SAB Biotherapeutics Warrant position as of Q1 2022 after selling out during the quarter.
  • CVI Holdings sold 58,320 SAB Biotherapeutics Warrant shares in Q1 2022, an estimated $104K.
  • CVI Holdings first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 3 quarters.
  • CVI Holdings's SAB Biotherapeutics Warrant position peaked at $161K in Q2 2021.
  • 13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2022.

Based on CVI Holdings's 13F filing for Q1 2022, filed 16 May 2022.